ProQR Therapeutics (PRQR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.45, -1.36% vs the prior close of $1.47.
- Volume 784.70K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PRQR dips 1.4% to $1.45, a 3-month low, 4 down days in a row. Closed at $1.45, -1.36% vs the prior close of $1.47. Day range $1.44–$1.49, opened at $1.48.
PRQR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PRQR dips 1.4% to $1.45, a 3-month low, 4 down days in a row
- Closed at $1.45, -1.36% vs the prior close of $1.47. Day range $1.44–$1.49, opened at $1.48.
- Volume was 784.70K shares, 1.0x its 50-day average of 822.46K.
- Price is -23.5% vs its 50-day average ($1.89) and -15.9% vs its 200-day average ($1.72).
- 52-week range $1.33–$3.10; today's close sits at 7% of that range, 53.2% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — PRQR dips 0.7% to $1.47, a 3-month low, 3 down days in a row
- Closed at $1.47, -0.68% vs the prior close of $1.48. Day range $1.43–$1.52, opened at $1.50.
- Volume was 1.08M shares, 1.3x its 50-day average of 825.80K.
- Price is -22.8% vs its 50-day average ($1.90) and -14.8% vs its 200-day average ($1.73).
- 52-week range $1.33–$3.10; today's close sits at 8% of that range, 52.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PRQR slides 8.6% to $1.48, a 3-month low
- Closed at $1.48, -8.64% vs the prior close of $1.62. Day range $1.48–$1.62, opened at $1.62.
- Volume was 1.18M shares, 1.5x its 50-day average of 813.30K.
- Price is -22.6% vs its 50-day average ($1.91) and -14.4% vs its 200-day average ($1.73).
- 52-week range $1.33–$3.10; today's close sits at 8% of that range, 52.3% below the 52-week high.
Oct 12, 2026 — PRQR dips 0.6% to $1.62 on 2.0x normal volume
- Closed at $1.62, -0.61% vs the prior close of $1.63. Day range $1.56–$1.70, opened at $1.62.
- Volume was 1.60M shares, 2.0x its 50-day average of 801.50K — unusually heavy trading.
- Price is -15.5% vs its 50-day average ($1.92) and -6.5% vs its 200-day average ($1.73).
- 52-week range $1.33–$3.10; today's close sits at 16% of that range, 47.7% below the 52-week high.
Oct 9, 2026 — PRQR jumps 3.8% to $1.63
- Closed at $1.63, +3.82% vs the prior close of $1.57. Day range $1.56–$1.63, opened at $1.57.
- Volume was 675.70K shares, 0.8x its 50-day average of 799.70K.
- Price is -15.0% vs its 50-day average ($1.92) and -6.1% vs its 200-day average ($1.74).
- 52-week range $1.33–$3.10; today's close sits at 17% of that range, 47.4% below the 52-week high.
Oct 8, 2026 — PRQR slides 3.7% to $1.57, a 3-month low, 3 down days in a row
- Closed at $1.57, -3.68% vs the prior close of $1.63. Day range $1.54–$1.62, opened at $1.62.
- Volume was 1.16M shares, 1.5x its 50-day average of 782.98K.
- Price is -18.3% vs its 50-day average ($1.92) and -9.7% vs its 200-day average ($1.74).
- 52-week range $1.33–$3.10; today's close sits at 14% of that range, 49.4% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — PRQR dips 1.2% to $1.63
- Closed at $1.63, -1.21% vs the prior close of $1.65. Day range $1.60–$1.64, opened at $1.63.
- Volume was 406.00K shares, 0.5x its 50-day average of 784.76K — lighter than usual.
- Price is -15.3% vs its 50-day average ($1.92) and -6.4% vs its 200-day average ($1.74).
- 52-week range $1.33–$3.10; today's close sits at 17% of that range, 47.4% below the 52-week high.
Oct 6, 2026 — PRQR dips 1.2% to $1.65
- Closed at $1.65, -1.20% vs the prior close of $1.67. Day range $1.62–$1.68, opened at $1.68.
- Volume was 504.60K shares, 0.6x its 50-day average of 788.29K.
- Price is -14.4% vs its 50-day average ($1.93) and -5.4% vs its 200-day average ($1.74).
- 52-week range $1.33–$3.10; today's close sits at 18% of that range, 46.8% below the 52-week high.
Oct 5, 2026 — PRQR rises 2.1% to $1.67
- Closed at $1.67, +2.14% vs the prior close of $1.63. Day range $1.60–$1.71, opened at $1.63.
- Volume was 720.60K shares, 0.9x its 50-day average of 785.24K.
- Price is -13.4% vs its 50-day average ($1.93) and -4.4% vs its 200-day average ($1.75).
- 52-week range $1.33–$3.10; today's close sits at 19% of that range, 46.1% below the 52-week high.
Oct 2, 2026 — PRQR rises 0.3% to $1.63
- Closed at $1.63, +0.31% vs the prior close of $1.63. Day range $1.62–$1.66, opened at $1.65.
- Volume was 622.60K shares, 0.8x its 50-day average of 784.59K.
- Price is -15.3% vs its 50-day average ($1.93) and -6.6% vs its 200-day average ($1.75).
- 52-week range $1.33–$3.10; today's close sits at 17% of that range, 47.3% below the 52-week high.
PRQR latest news & SEC filings
Every SEC filing by or about PRQR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 23, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- De Boer Daniel Anton bought 200,000 shares at $1.77 (≈$354.00K) on Jul 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 29, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 24, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Filius Bart bought 150,000 shares at $1.72 (≈$258.00K) on Jul 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 15, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 15, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 15, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- De Boer Daniel Anton bought 150,000 shares at $1.74 (≈$261.00K) on Jul 9, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- De Boer Daniel Anton bought 150,000 shares at $1.59 (≈$238.50K) on Jul 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade PRQR
- How much it moves: over the last 20 sessions the average daily move was 2.38% (largest 10.5%).
- Liquidity: about 798.93K shares (≈$1.16M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.45 vs a range of $1.33–$3.10 (7% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 5 open-market buys, 0 sales; latest: Boer Daniel Anton De bought 200,000 shares on Jul 31, 2026.
- Latest filings: 6-K Sep 23, 2026; 6-K Sep 9, 2026; 6-K Aug 13, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PRQR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.48 | 1.49 | 1.44 | 1.45 | 784.70K |
| Oct 14, 2026 | 1.50 | 1.52 | 1.43 | 1.47 | 1.08M |
| Oct 13, 2026 | 1.62 | 1.62 | 1.48 | 1.48 | 1.18M |
| Oct 12, 2026 | 1.62 | 1.70 | 1.56 | 1.62 | 1.60M |
| Oct 9, 2026 | 1.57 | 1.63 | 1.56 | 1.63 | 675.70K |
| Oct 8, 2026 | 1.62 | 1.62 | 1.54 | 1.57 | 1.16M |
| Oct 7, 2026 | 1.63 | 1.64 | 1.60 | 1.63 | 406.00K |
| Oct 6, 2026 | 1.68 | 1.68 | 1.62 | 1.65 | 504.60K |
| Oct 5, 2026 | 1.63 | 1.71 | 1.60 | 1.67 | 720.60K |
| Oct 2, 2026 | 1.65 | 1.66 | 1.62 | 1.63 | 622.60K |
| Oct 1, 2026 | 1.66 | 1.69 | 1.55 | 1.63 | 1.97M |
| Sep 30, 2026 | 1.67 | 1.69 | 1.64 | 1.66 | 678.50K |
| Sep 29, 2026 | 1.66 | 1.70 | 1.63 | 1.65 | 382.00K |
| Sep 28, 2026 | 1.69 | 1.69 | 1.62 | 1.65 | 471.60K |
| Sep 25, 2026 | 1.72 | 1.72 | 1.63 | 1.65 | 584.80K |
| Sep 24, 2026 | 1.70 | 1.73 | 1.66 | 1.71 | 601.40K |
| Sep 23, 2026 | 1.89 | 1.89 | 1.69 | 1.70 | 1.14M |
| Sep 22, 2026 | 1.87 | 1.91 | 1.84 | 1.90 | 433.40K |
| Sep 21, 2026 | 1.86 | 1.88 | 1.82 | 1.86 | 406.70K |
| Sep 18, 2026 | 1.89 | 1.89 | 1.83 | 1.83 | 567.00K |
About ProQR Therapeutics
ProQR Therapeutics (PRQR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LEIDEN. State of incorporation: Netherlands. Fiscal year ends December 31. SEC CIK 1612940.
PRQR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Begona Carreno-Gomez | Director | Mar 18, 2026 |
| Bart Filius | Director | Jul 21, 2026 |
| Theresa Heggie | Director | Mar 18, 2026 |
| Gylvin Lykke Hinsch | Director | Jun 30, 2026 |
| Alison Frances Lawton | Director | Mar 18, 2026 |
| Martin Alexander Maier | Director | Mar 18, 2026 |
| Gerardus Johannes Platenburg | Chief Scientific Officer | Mar 18, 2026 |
| James Samuel Shannon | Director | Mar 18, 2026 |
| Domenico Valerio | Director | Mar 18, 2026 |
| Boer Daniel Anton De | Chief Executive Officer | Aug 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dennis Hom | Chief Financial Officer | Mar 18, 2026 |
| Gerardus Johannes Platenburg | Chief Scientific Officer | Mar 18, 2026 |
| Boer Daniel Anton De | Chief Executive Officer | Aug 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 31, 2026 | Boer Daniel Anton De | Buy | 200,000 | $1.77 |
| Jul 17, 2026 | Bart Filius | Buy | 150,000 | $1.72 |
| Jul 9, 2026 | Boer Daniel Anton De | Buy | 150,000 | $1.74 |
| Jul 7, 2026 | Boer Daniel Anton De | Buy | 150,000 | $1.59 |
| Jun 26, 2026 | Bart Filius | Buy | 150,000 | $1.54 |
PRQR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
PRQR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PRQR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.